Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02700230 · ClinicalTrials.gov registry record · Phase 1

Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

A Phase 1 study of Neurofibromatosis Type 1 and Recurrent Malignant Peripheral Nerve Sheath Tumor, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target
1
Study location

NCT02700230 is a Phase 1 study of Neurofibromatosis Type 1 and Recurrent Malignant Peripheral Nerve Sheath Tumor that has completed, run by Mayo Clinic. The registered enrollment target is 9 participants, below the 160-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02700230, a Phase 1 study of Neurofibromatosis Type 1 and Recurrent Malignant Peripheral Nerve Sheath Tumor, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and the best dose of a vaccine therapy in treating patients with malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period of improvement (recurrent). Vaccines made from a gene-modified virus may kill tumor cells expressing a gene called neurofibromin 1 (NF1) without affecting surrounding normal cells and may also help the body build an effective immune response to kill tumor cells.

Conditions Studied

Neurofibromatosis Type 1 Recurrent Malignant Peripheral Nerve Sheath Tumor Metastatic Malignant Peripheral Nerve Sheath Tumor

Interventions

  • PROCEDURE Computed Tomography
  • OTHER Quality-of-Life Assessment
  • OTHER Laboratory Biomarker Analysis
  • PROCEDURE Single Photon Emission Computed Tomography
  • BIOLOGICAL Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2017-03-22
Est. Completion 2024-04-17
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02700230

The ClinicalTrials.gov registry entry for NCT02700230 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (94% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Neurofibromatosis Type 1 appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT02700230 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT02700230 about?

NCT02700230 is a clinical study titled "Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery". This phase I trial studies the side effects and the best dose of a vaccine therapy in treating patients with malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period of improvement (recurrent). Vaccines made from a gene-modified virus m...

What is the current status of trial NCT02700230?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2017-03-22. Estimated completion is 2024-04-17.

What conditions does trial NCT02700230 study?

This clinical trial studies the following conditions: Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor, Metastatic Malignant Peripheral Nerve Sheath Tumor.

What interventions are being tested in trial NCT02700230?

The interventions under investigation include: Computed Tomography (PROCEDURE), Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Single Photon Emission Computed Tomography (PROCEDURE), Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter (BIOLOGICAL).

Who is sponsoring clinical trial NCT02700230?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02700230 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neurofibromatosis Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neurofibromatosis Type 1

All registered trials for this condition

Recurrent Malignant Peripheral Nerve Sheath Tumor

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.